Hillstream BioPharma Licenses Technology To Develop Proprietary HER2 And HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, And Ovarian Cancers
Portfolio Pulse from Happy Mohamed
Hillstream BioPharma (NASDAQ:HILS) has signed an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes. The aim is to develop proprietary multi-format biologics, including bi-specific antibodies, and antibody drug conjugates (ADCs) to combat drug resistant cancers such as HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer.
July 06, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hillstream BioPharma's partnership with ABSI to develop antibodies for drug-resistant cancers could potentially lead to new revenue streams if the development is successful.
The licensing agreement with ABSI allows Hillstream BioPharma to develop new biologics for drug-resistant cancers. If successful, this could lead to new treatments and potential revenue streams for the company. However, the development process is complex and success is not guaranteed.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100